The Association of American Universities's grant-rate tracker reads below 50 percent again this Sunday — the fifth consecutive weekly Sunday in which the rolling four-week approval rate at the National Institutes of Health has printed under the historical norm of 55 to 62 percent. [1] STAT's April 30 reconstruction of the agency's approval pipeline, the most granular published view of the operational gap, named the underlying mechanics: a Department of Government Efficiency termination order in February killed more than 600 active grants representing between $6.9 billion and $8.2 billion in committed obligations, R01 deadlines were silently shifted to June 5 in March, and the FY2026 appropriation Congress held at $47.22 billion has not been translating into approved obligations at the pre-2025 cadence. [2] The paper's Saturday weekly reading ran the same finding; Sunday's print extends the streak by one week.

The structural problem is not appropriation. Congress restored the NIH topline in the December 2025 continuing resolution and the March omnibus held it at $47.22 billion through fiscal year 2026 — within $300 million of the agency's last pre-cuts authorization. [3] The problem is the disconnect between the appropriated dollars and the dollars that move from the Office of Management and Budget through the institutes' grant-management offices into approved Notice of Award letters in principal investigators' hands.

That disconnect runs through two operational chokepoints. The first is the OMB apportionment cycle — the quarterly process by which appropriated funds are released to the operating agencies. NIH's first-quarter FY2026 apportionment arrived 11 days late in October; the second arrived 17 days late in January; the third, due February 1, was issued in three tranches over six weeks. [4] Each delay compresses the window in which institute-level grant-management offices can issue awards before the fiscal-year ramp ends in September. The second chokepoint is institutional. The DOGE termination order in February cut a layer of senior grant-management staff at three institutes — the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, and the National Heart, Lung, and Blood Institute — whose workflow capacity has not been backfilled. Their R01 review cadence has slowed by roughly 35 percent against the prior year.

The June 5 R01 deadline is the visible artifact. R01 is the workhorse five-year investigator-initiated grant that funds the bulk of academic biomedical research in the United States. The standard cycle has three R01 deadlines per year — February 5, June 5, and October 5 — with a roughly 21 to 26 percent funded rate at study-section review. [5] The June 5 deadline this week will produce a submission volume estimated by the Federation of American Societies for Experimental Biology at 9 percent above prior-year baseline, on accumulated holds from the February cycle that bridged into June. The institutes' capacity to process that surge has, on the AAU tracker's current reading, not been restored. [1]

The downstream consequence is what biomedical chairs describe in private as a quiet hiring freeze across the academic medical centers — not announced, not budgeted, but operating. A post-doctoral fellow whose R01 funding does not arrive in the third quarter does not get a second-year contract. A principal investigator who is denied or held in review does not commit to the next graduate student. The compounding has begun to show in the application data — submissions for K99 mentored career-development grants are down 14 percent year-over-year in the first three quarters of FY2026, the steepest contraction in the program's recorded history.

The Sunday-of-Memorial-Day reading is therefore mechanical. The appropriated $47.22 billion is not the binding number. The binding number is the share of that appropriation that moves from authorized to obligated in fiscal year 2026, and on Sunday's AAU print, that share is still below 50 percent. The federal biomedical research enterprise is being underspent by Congress's own measure, on a Memorial Day weekend in which the only related public statement from any senior administration health official was the FDA commissioner's silent resignation letter twelve days ago.

-- NORA WHITFIELD, Chicago